Raymond James & Associates’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Raymond James & Associates’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,616	Closed	-$736K	–	3725
2018 Q3	$736K	Buy	10,616 +1,015	+11%	+$76.9K	﹤0.01%	2437
2018 Q2	$726K	Buy	9,601 +1,611	+20%	+$101K	﹤0.01%	2418
2018 Q1	$421K	Buy	+7,990	New	+$465K	﹤0.01%	2677
2017 Q4	–	Sell	-6,359	Closed	-$379K	–	3546
2017 Q3	$379K	Buy	6,359 +1,704	+37%	+$103K	﹤0.01%	2643
2017 Q2	$367K	Buy	4,655 +766	+20%	+$62.6K	﹤0.01%	2601
2017 Q1	$323K	Buy	3,889 +582	+18%	+$43.3K	﹤0.01%	2661
2016 Q4	$262K	Buy	+3,307	New	+$240K	﹤0.01%	2724

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Raymond James & Associates's EGRX Position: Q4 2018 in Review

Raymond James & Associates sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 10,616 shares — an estimated $736K sold.

Raymond James & Associates first reported a position in EGRX in Q4 2016 and held it in 7 quarters. The position peaked at $736K in Q3 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

Raymond James & Associates reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Raymond James & Associates sold 10,616 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $736K.
Raymond James & Associates first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2016 and held it in 7 quarters.
Raymond James & Associates's Eagle Pharmaceuticals, Inc. position peaked at $736K in Q3 2018.
182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on Raymond James & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.